BTIG announced today that Lin Yu, PhD, has joined the firm to launch a new Healthcare Royalty Monetization practice from within its Investment Banking unit. BTIG’s healthcare expertise makes the firm the ideal partner for its corporate and institutional investor clients exploring the purchase and sale of royalty streams.
Some of the core Healthcare Royalty Monetization sellers of interest include drug development companies, academic institutions and inventors. Royalty monetization is an attractive, non-dilutive financing vehicle for sellers who benefit from increased funding from immediate payment, de-risked from unknown future cash flow. It also presents opportunities for participants to potentially profit from outperformance of the asset. By facilitating introductions between buyers and sellers, BTIG professionals will help identify transactions for its institutional investor clients to participate in royalty payments.
Dr. Yu joins BTIG’s Healthcare Investment Banking division as a Managing Director in San Francisco, where he will lead the firm’s new Healthcare Royalty Monetization business. Prior to BTIG, he was a Principal on the Healthcare Private Equity Team at KKR dedicated to its royalty and private credit strategy. Previously, Dr. Yu was a Director of Investment Research and Analysis at DRI Capital, a healthcare royalty-focused private equity firm. Earlier in his career, he was an Equity Research Analyst covering medical devices and technologies at Cowen & Co. Dr. Yu earned a PhD and an MS from Columbia University in chemical engineering, where he focused his research on next-generation DNA sequencing technologies. He earned a BS in chemical engineering from The Cooper Union for Advancement of Science and Art.
“We are confident that Lin can add extensive value as an advisor for clients interested in Healthcare Royalty Monetization,” noted K.C. Stone, Managing Director and Head of Healthcare Investment Banking at BTIG. “Clients can expect a differentiated level of service from our team as we actively target potential investments and investors, provide thoughtful analysis, work to obtain premium value for sellers and buyers and solicit important feedback throughout the negotiation of agreements.”
BTIG Investment Banking focuses on capital raising and financial advisory services, specialized in private and public offerings of equity, debt and equity-linked securities, M&A and restructuring advice. The firm’s healthcare bankers offer solutions and services across the biotechnology, life science tools, medical technology, diagnostic tools, digital health and specialty pharmaceuticals sectors as well as a vast array of banking and capital markets products.
“BTIG is committed to providing solutions for both corporate and institutional clients,” said Scott Kovalik, Co-Founder and Chief Executive Officer of BTIG. “With Lin leading our new Healthcare Royalty Monetization business, we are offering another channel for clients to monetize their intellectual property and capture new streams of revenue.”
Since 2015, BTIG has executed more than $130 billion in total transaction value across 350-plus announced transactions. The firm’s investment banking products include mergers and acquisitions, capital markets advisory, IPOs, follow-on offerings, ATMs, SPACs, private placements, convertibles, debt, buybacks, liquidity solutions, venture capital, private equity and private capital. Clients benefit from proprietary and actionable market intelligence, and BTIG’s comprehensive understanding of financial dynamics. Aftermarket services include trading coverage and corporate access, connecting issuers with the buy side.
BTIG is a global financial services firm specializing in institutional trading, investment banking, research and related brokerage services. With an extensive global footprint and more than 600 employees, BTIG, LLC and its affiliates operate out of 18 cities throughout the U.S., and in Europe, Asia and Australia. BTIG offers execution, expertise and insights for equities, equity derivatives, ETFs and fixed income, currency and commodities (futures, commodities, foreign exchange, interest rates, credit, and convertible and preferred securities). The firm’s core capabilities include global execution, portfolio, electronic and outsource trading, transition management, investment banking, prime brokerage, capital introduction, corporate access, research and strategy, commission management and more.